Cargando…

Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients

SIMPLE SUMMARY: In this short communication, we present three cases of patients with symptomatic, synchronous brain metastases of otherwise locally limited non-small cell lung cancer. The patients received local ablative treatment of the brain metastases followed by neoadjuvant immunochemotherapy wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koch, Agnes, Sponholz, Stefan, Trainer, Stephan, Stratmann, Jan, Sebastian, Martin, Rauch, Maximilian, Wolff, Robert, Steinbach, Joachim P., Ronellenfitsch, Michael W., Urban, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030832/ https://www.ncbi.nlm.nih.gov/pubmed/35448155 http://dx.doi.org/10.3390/curroncol29040181

Ejemplares similares

Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression
por: Jia, Wenxiao, et al.
Publicado: (2021)

Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study
por: Wallrabenstein, Till, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
por: Ulas, Ezgi B., et al.
Publicado: (2023)

Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy
por: Zhai, Wen-Yu, et al.
Publicado: (2023)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

MRI characteristics in treatment for cerebral melanoma metastasis using stereotactic radiosurgery and concomitant checkpoint inhibitors or targeted therapeutics
por: Rauch, Maximilian, et al.
Publicado: (2021)

What if: A retrospective reconstruction of resection cavity stereotactic radiosurgery to mimic neoadjuvant stereotactic radiosurgery
por: Acker, Gueliz, et al.
Publicado: (2023)

Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery
por: Gao, Hong Xiang, et al.
Publicado: (2018)

Corrigendum: What if: a retrospective reconstruction of resection cavity stereotactic radiosurgery to mimic neoadjuvant stereotactic radiosurgery
por: Acker, Gueliz, et al.
Publicado: (2023)

Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
por: Cai, Wenhan, et al.
Publicado: (2022)

A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Yang, Yalan, et al.
Publicado: (2023)

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study
por: Fei, Kailun, et al.
Publicado: (2023)

Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
por: Li, Kaiyuan, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial)
por: Huang, Yingying, et al.
Publicado: (2023)

Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition
por: Urban, Hans, et al.
Publicado: (2020)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer
por: Han, Wu, et al.
Publicado: (2023)

Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
por: Chen, Jiawei, et al.
Publicado: (2022)

Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer
por: Huang, Shu Jie, et al.
Publicado: (2022)

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa
por: Gao, Lei, et al.
Publicado: (2022)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

“Major pathologic response” in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy
por: Deng, Hongsheng, et al.
Publicado: (2023)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Immunochemotherapy for Richter syndrome: current insights
por: Puła, Bartosz, et al.
Publicado: (2019)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
por: Yadagiri, Ganesh, et al.
Publicado: (2023)

Bifidobacterium in anticancer immunochemotherapy: friend or foe?
por: Procaccianti, Giorgia, et al.
Publicado: (2023)

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

(18)F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
por: Wang, Shuohua, et al.
Publicado: (2023)

Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy
por: Baech, Joachim, et al.
Publicado: (2022)

Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real‐world retrospective study
por: Lin, Guang‐Tan, et al.
Publicado: (2023)

Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
por: Feng, Jifeng, et al.
Publicado: (2023)

Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments
por: Song, Xin-Yun, et al.
Publicado: (2023)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
por: Badellino, Serena, et al.
Publicado: (2022)

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
por: Gaitzsch, Erik, et al.
Publicado: (2021)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
por: Roller, John F., et al.
Publicado: (2022)

The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study
por: Feng, Jifeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t5b3qd6d78r6qipmrjshf21cjt